Using ALS Patient-Derived Motor Neurons to Study TDP-43 Mislocalization

Sponsored by:

Date:

January 21, 2026

Time (ET):

11:00 AM

Duration (min):

In this webinar, Vera Evanson, PhD presents how iPSC-derived ALS models reproduce hallmark disease phenotypes and their use in evaluating drug responses.

Amyotrophic Lateral Sclerosis (ALS) remains one of the most challenging neurodegenerative diseases to model and treat. Dr. Evanson will discuss how iPSC-derived ALS models reproduce TDP-43 mislocalization and how these models can be leveraged to evaluate drug responses and TDP-43 dynamics. Join to learn how Ricoh Biosciences' transcription factor-based differentiation platform enables rapid, reproducible generation of motor neurons and how these physiologically relevant models can accelerate your drug discovery, target validation, and phenotypic screening efforts in ALS research.

Presenters

Vera Evanson

Ricoh Biosciences (Research & Development)

Lead Scientist

Dr. Vera-Marie Evanson is an R&D Lead Scientist at Ricoh Biosciences and a lead scientist on ALS assay development, working with partners to refine our disease-modeling platform for their research needs. She specializes in assay design, high-content imaging, and image analysis, trained at Radboud University and Johns Hopkins.

Ricoh Biosciences

Ricoh Biosciences, formerly Elixirgen Scientific, is a biotechnology company using proprietary human iPSC differentiation technology to accelerate drug discovery, disease modeling, and cell therapy development. It provides high-quality, scalable cellular platforms and assays to support research and therapeutic innovation.

Content Partners

Scientist.com

Scientist.com is the world’s largest and first platform built for the intricacies of scientific outsourcing.

We help pharmaceutical and biotechnology organizations discover, engage, manage, and scale relationships with the providers that support every stage of the pipeline—from discovery and preclinical research to clinical development, manufacturing, medical affairs, and commercialization. Through a centralized platform, organizations can access a global network of 6,000+ providers, streamline sourcing and procurement workflows, maintain compliance, manage supplier relationships, and leverage data-driven insights to make faster, more informed decisions.

Today, Scientist.com supports more than 130 life science organizations, including 24 of the world's top 30 pharmaceutical companies, helping teams reduce operational complexity, accelerate timelines, and bring innovations to patients faster. Our mission is to make it possible to cure all human disease by 2050.

‍

Topics

Pharmacology

Disease Models

Clinical Trials

Using ALS Patient-Derived Motor Neurons to Study TDP-43 Mislocalization

Presenters

Vera Evanson

Sponsor

Ricoh Biosciences

Content Partners

Scientist.com

Topics

Watch Now

Related Content

Engineering Neuromodulation for Cardiovascular Instability

Advancing the Manufacture of Mesenchymal Stromal Cells and Derived Extracellular Vesicles in Stirred-Tank Bioreactors Through Enhanced Bioprocess Control

From Clinical Data to Actionable Assets for Pharmaceutical R&D

Advancing the Manufacture of Mesenchymal Stromal Cells and Derived Extracellular Vesicles in Stirred-Tank Bioreactors Through Enhanced Bioprocess Control

Functional Ultrasound Demonstration and Live Q&A: Iconeus One, a Pioneer in Real-Time Whole-Brain Imaging

Precision in Human Biological Samples: Leveraging Regulatory Rigor and Deep Data for Advanced Disease Research

Detecting Early Synaptic Failure in Prion Disease Using Organoid Models

Improving Preclinical Decision-Making in Obesity and CKD with Translational In Vivo Phenotyping

Bridging Mouse Models and Human Inflammatory Bowel Disease: in vivo Pharmacology, Histology and Biomarkers

Skeletal Muscle Circadian Clocks: Keeping Time for Systemic Health

Screening the Unscreenable: Expanding the Reach of Drug Discovery

High-Throughput-qPCR and Transcriptomics: Powering the Next Generation of Drug Discovery

From Clinical Data to Actionable Assets for Pharmaceutical R&D

Network meta-analysis and its role in evidence-based decision-making

Addressing Orphan and Rare Diseases - A Cutting Edge Conversation

Joint Clinical Assessment 2025: Pioneering Pathways for Oncology, Advanced Therapies & Rare Diseases

RWE reality check: Routine patient health records and regulatory requirements

Survival Analysis for Immature Data: A Review of Techniques and Lessons Learned

Market Access - Transforming BioTech Commercial Decisions?

Delphi Panels: What Are They Good For?

Patient Voices Matter: Transforming Industry-Sponsored Real-World Evidence with Patient-Centric Approaches

Strategies to Optimize Commercialization of Oncology Treatments for Younger Adults

Navigating the Clinical Outcomes Maze: An Overview of Clinical Outcomes Assessments and Why Training Matters

EU HTA Joint Clinical Assessments: Navigating Potential Challenges Ahead of 2025

Cell & Gene Therapies - Beginning with the End in Mind

Bridging the Gap: Strategies for Patient-Centered Real-World Evidence in Rare Diseases

Voices to Trials: Engaging Patients in Clinical Trial Design

Clinical Trial Innovation: How Healthcare Technology is Evolving

Transforming clinical research: Scaling real-world data across diseases with expert-led AI

Notice of Pre-Application Webinar for RFA-AG-24-009, "Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) Real-World Data Platform (U54 Clinical Trial Optional)"

Patient Data: Opportunities for Rare Diseases, Cell and Gene Therapies, and Oncology

Connecting Real-World Data and Domain Expertise to Enhance Trial Design and Planning

Trials and tribulations of drug development

Webinar Series: Early patient preferences for patient-focused drug development

Keeping pace with the evolving global landscape in vaccine development

Patient centric sampling in pediatric clinical trials- successes, challenges and how to overcome them

How to Supercharge Real World Evidence Generation in Phase IV Trials

Using AI and Technology to Streamline Post-Stroke Patient Journeys to Cardiology

Decentralized trial solutions for complex clinical trials

Looking Beyond Survival Data: Understanding the Value of Non-OS Endpoints in Oncology Reimbursement Decision-Making

Overcoming Patient Recruitment Challenges in Rare Disease Trials - September 28th

Optimize Your Decentralized Clinical Trials with Real-World Data

Clinical Development Innovations

Cutting Edge Conversations: Fighting Neurodegenerative Diseases

Cutting Edge Conversations: Discovering New Innovations in Oncology

Cutting Edge Conversations: Addressing COVID-19 During Uncertainty

Cutting Edge Conversations: Finding Solutions to the Obesity Epidemic

Marketplaces Drive Faster Science: HEOR, RWE & Market Access Sourcing

Translational Success in Inflammasome Drug Discovery: How Advanced Models and Integrated Assays Can Reduce Attrition

How to Avoid Expensive Redesign Cycles in Antibody Discovery

Recent Advances in Crystalline Polymorphism Research in Drug Development

Engineering Neuromodulation for Cardiovascular Instability

Improving Confidence in Thyroid Hormone Disruption Assessment Using a Novel Human-Relevant In Vitro Model

Accelerating Antibody Discovery: Integrating Microfluidics, HT Expression, and Early Developability Platform

Beyond Exposure: Integrating PK/PD for Translational Predictive Power

Illuminating the Brain: Advances in Neurobiology

Fulfilling the Gap: Innovative Critical Reagents for Non-Human Primate Preclinical Studies

Advancing ADC Development: Leveraging AI and Translational Preclinical Models to Improve Clinical Predictability

Scaling AAV9 Manufacturing: A Blueprint for Clinical-Grade Gene Therapy Production

Human iPSC-Derived Sensory Neurons for Functional Sensory Biology and Pharmacology Research

From Biopsy to Better Decisions: Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer

Accelerating Conjugation Process Development for Next-Generation ADCs: Key Considerations and Platform Strategies

Epigenomics at 360 in Liquid Biopsy: Approaches and Case Studies for Biomarker Discovery and Drug Development

The Sound of Science: Mapping the Tumor Microenvironment for Advanced Therapeutic Strategies

Next-Generation TCR-Like Antibodies With Improved Specificity Profiles

ADC Payload-Linker CMC Process Development Strategy

Opening a New Window: Stable Long-Term Imaging of Dura Mater-Transplanted Pancreatic Islets in Awake Mice

De-Risking Immunotherapy Targets with Next-Gen HLA Discovery Platforms

The Expert Approach to Preclinical Indirect Calorimetry Experiments

Photoreceptor Cell Therapy to Treat Advanced Retinal Degeneration